Condition

Genital prolapse

Clinical trials and treatment information for Genital prolapse

124.4M
People Affected
60
Active Trials
2.5M
New Cases/Year
486
Deaths/Year

Treatment Rankings

Ranked by evidence volume first. Medicine has spent centuries ranking things by vibes. This is an improvement.

1
Laparoscopic/Robotic Sacrocolpopexy
90% Effectiveness• 95% Confidence• 65% Safety• 6 trials• 8K participants
HIGH EvidenceGood Value
Find Trials

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
65
DangerousModerateSafe

Time to Effect

Immediate anatomical correction; symptom resolution 6-12 weeks post-op

Duration

One-time surgery, recovery 6-8 weeks

Response Rate

90%

Remission Rate

82%

Number Needed to Treat (NNT)

7

Number Needed to Harm (NNH)

15

Common Side Effects:

Post-operative pain: 35%
Infection: 5%
Bleeding/Hematoma: 5%
Mesh erosion/exposure: 10%
Dyspareunia (painful intercourse): 10%
Urinary symptoms (e.g., urgency, stress incontinence): 15%
Recurrence of prolapse: 7%

Annual Cost of Care

Drug Cost

$0

Monitoring

$500

Side Effects

$700

Total Annual

$21,200

Cost-Effectiveness

GOOD

QALYs Gained

1

ICER

$65,000/QALY

Cost per Remission

$25,853.66

Cost per Responder

$23,555.56

Treatment Outcomes
Primary Outcomes
Pelvic Floor Symptom Distress (PFDI-20 score)PFDI-20 score: 100/300
-70% (-70 points (to 30/300))
Maximal Prolapse Beyond Hymen2 cm
-100% (-2 cm (to 0 cm or less))
Bowel Distress (BDI-6 score from PFDI-20)BDI-6 score: 40/100
-50% (-20 points (to 20/100))
Secondary Benefits
Pelvic Floor Impact Questionnaire (PFIQ-7 score)PFIQ-7 score: 50/100
-60% (-30 points (to 20/100))
Sexual Function (PISQ-12 score)PISQ-12 score: 25/48
+20% (+5 points (to 30/48))
Urinary Distress (UDI-6 score from PFDI-20)UDI-6 score: 45/100
-40% (-18 points (to 27/100))
Common Side Effects
Post-operative pain
+35%
Infection
+5%
Bleeding/Hematoma
+5%
2
Vaginal Pessaries
75% Effectiveness• 90% Confidence• 85% Safety• 7 trials• 10K participants
HIGH EvidenceExcellent ValueDose: Various sizes and types, fitted by clinician
Find Trials

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
85
DangerousModerateSafe

Time to Effect

Immediate symptom relief once fitted

Duration

Long-term, often lifelong

Response Rate

80%

Remission Rate

0%

Number Needed to Treat (NNT)

4

Number Needed to Harm (NNH)

15

Common Side Effects:

Vaginal discharge: 40%
Vaginal irritation/erosion: 15%
Vaginal infection: 8%
Odor: 15%
Pain/discomfort: 10%

Annual Cost of Care

Drug Cost

$0

Monitoring

$600

Side Effects

$100

Total Annual

$700

Cost-Effectiveness

EXCELLENT

QALYs Gained

0.4

Cost per Responder

$875

Treatment Outcomes
Primary Outcomes
Pelvic Organ Prolapse Symptom Scale (POP-SS)POP-SS score: 12/28 (moderate symptoms)
-50% (-6 points on POP-SS)
Severity of Vaginal Bulge (Visual Analog Scale)VAS score: 7/10 (severe bulge sensation)
-60% (-4.2 points on VAS)
Pelvic Organ Prolapse Quantification (POP-Q) - Most Prolapsed Point (MPP)+3 cm beyond hymen (e.g., Stage III prolapse)
-133.3% (-4 cm (e.g., from +3cm to -1cm))
Secondary Benefits
Pelvic Floor Impact Questionnaire (PFIQ-7)PFIQ-7 score: 15/30 (moderate impact on daily life)
-40% (-6 points on PFIQ-7)
Urinary Distress Inventory (UDI-6)UDI-6 score: 10/24 (moderate urinary distress)
-30% (-3 points on UDI-6)
Female Sexual Function Index (FSFI)FSFI score: 15/36 (moderate sexual dysfunction)
+20% (+3 points on FSFI)
Common Side Effects
Vaginal discharge
+40%
Vaginal irritation/erosion
+15%
Vaginal infection
+8%
3
Native Tissue Repair (Colporrhaphy)
70% Effectiveness• 85% Confidence• 65% Safety• 1 trials• 10K participants
MODERATE EvidenceGood Value
Find Trials

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
65
DangerousModerateSafe

Time to Effect

Immediate anatomical correction; symptom resolution 4-8 weeks post-op

Duration

One-time surgery, recovery 6-8 weeks

Response Rate

75%

Remission Rate

65%

Number Needed to Treat (NNT)

3

Number Needed to Harm (NNH)

7

Common Side Effects:

Post-operative pain: 40%
Infection: 7%
Bleeding/Hematoma: 7%
Dyspareunia (painful intercourse): 15%
Urinary symptoms (e.g., urgency, stress incontinence): 15%
Recurrence of prolapse: 25%

Annual Cost of Care

Drug Cost

$0

Monitoring

$500

Side Effects

$500

Total Annual

$13,000

Cost-Effectiveness

GOOD

QALYs Gained

0.7

ICER

$50,000/QALY

Cost per Remission

$20,000

Cost per Responder

$17,333.33

Treatment Outcomes
Primary Outcomes
Objective Prolapse Point (POP-Q Ba point)POP-Q Ba point: +1.5 cm
-166.67% (-2.5 cm (from +1.5 cm to -1.0 cm))
Pelvic Floor Distress Inventory (PFDI-20) Total ScorePFDI-20 score: 120/300
-50% (-60 points)
P-QOL Prolapse Symptoms Domain ScoreP-QOL Prolapse Symptoms score: 60/100
-66.67% (-40 points)
Secondary Benefits
Pelvic Floor Impact Questionnaire (PFIQ-7) Total ScorePFIQ-7 score: 80/300
-50% (-40 points)
P-QOL Sexual Domain ScoreP-QOL Sexual Domain score: 30/100
+100% (+30 points)
Urinary Distress Inventory (UDI-6) ScoreUDI-6 score: 60/100
-50% (-30 points)
Common Side Effects
Post-operative pain
+40%
Infection
+7%
Bleeding/Hematoma
+7%
4
Pelvic Floor Muscle Training (PFMT)
65% Effectiveness• 85% Confidence• 95% Safety• 2 trials• 15K participants
HIGH EvidenceExcellent ValueDose: 3-5 sets of 8-12 contractions, 3 times daily
Find Trials

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
95
DangerousModerateSafe

Time to Effect

3-6 months

Duration

Lifelong for maintenance, initial intensive period 3-6 months

Response Rate

70%

Remission Rate

45%

Number Needed to Treat (NNT)

7

Common Side Effects:

Muscle soreness: 5%
Vaginal discomfort during exercise: 3%

Annual Cost of Care

Drug Cost

$0

Monitoring

$300

Side Effects

$0

Total Annual

$300

Cost-Effectiveness

EXCELLENT

QALYs Gained

0.2

Cost per Remission

$666.67

Cost per Responder

$428.57

Treatment Outcomes
Primary Outcomes
Point Ba position (POP-Q)+1 cm (1 cm below hymen)
-50% (-0.5 cm)
Pelvic Floor Muscle Strength (Oxford Scale)Grade 2/5
+50% (Improved by 1 grade)
Pelvic Floor Distress Inventory (PFDI-20) Total Score150/300 points
-33.3% (-50 points)
Perceived Vaginal Bulge Severity (VAS 0-10)7/10
-28.6% (-2 points)
Secondary Benefits
Pelvic Floor Impact Questionnaire (PFIQ-7) Total Score120/300 points
-25% (-30 points)
Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ-12) Total Score28/48 points
+21.4% (+6 points)
International Consultation on Incontinence Questionnaire - UI Short Form (ICIQ-UI SF)10/21 points
-40% (-4 points)
Common Side Effects
Muscle soreness
+5%
Vaginal discomfort during exercise
+3%
5
Vaginal Estrogen (Topical)
55% Effectiveness• 80% Confidence• 90% Safety• 100 trials• 10K participants
HIGH EvidenceExcellent ValueDose: 0.5g applicator 2-3 times/week or vaginal ring/tablet (various doses)
Find Trials

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
90
DangerousModerateSafe

Time to Effect

2-4 weeks

Duration

Long-term, often lifelong

Response Rate

70%

Remission Rate

0%

Number Needed to Treat (NNT)

6

Common Side Effects:

Vaginal discharge/irritation: 7%
Breast tenderness: 3%

Annual Cost of Care

Drug Cost

$800

Monitoring

$50

Side Effects

$20

Total Annual

$870

Cost-Effectiveness

EXCELLENT

QALYs Gained

0.1

Cost per Responder

$1,242.86

Treatment Outcomes
Efficacy Outcomes
Overall Effectiveness
+55%
Response Rate
+70%
Common Side Effects
Vaginal discharge/irritation
+7%
Breast tenderness
+3%